4506 — Sumitomo Pharma Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapNeutral

Annual income statement for Sumitomo Pharma Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	482,732	515,952	560,035	555,544	314,558
Cost of Revenue
Gross Profit	353,687	378,307	402,919	377,050	188,030
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	399,493	444,728	499,801	632,523	669,417
Operating Profit	83,239	71,224	60,234	-76,979	-354,859
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	83,947	77,851	82,961	-47,920	-323,114
Provision for Income Taxes
Net Income After Taxes	35,918	36,829	40,600	-96,714	-314,929
Minority Interest
Net Income Before Extraordinary Items
Net Income	40,753	56,219	56,413	-74,512	-314,969
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	40,753	56,219	56,413	-74,512	-314,969
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	140	164	142	-150	-506
Dividends per Share